Effect of toripalimab plus cetuximab combined with radiotherapy on patient with locally advanced high-grade parotid mucoepidermoid carcinoma

Mucoepidermoid carcinoma (MEC) is the most common malignant tumor of the salivary glands, accounting for approximately one-third of all salivary gland tumors. Based on the proportion of epidermoid and mucous cells, MEC is classified into three grades. High-grade MEC, an extremely rare malignancy, has a higher proportion of epidermoid cells and a poorer prognosis. Currently, there has been no standard treatment for patients with positive surgical margins after parotidectomy. This case report describes the successful treatment of a patient with high-grade parotid MEC and positive surgical margins using toripalimab plus cetuximab combined with radiotherapy, who achieved complete response one month after the completion of treatment. We report a case in which a patient with locally advanced high-grade parotid MEC with R2 resection achieved a complete response after postoperative adjuvant radiotherapy combined with toripalimab and cetuximab. • Innovative Therapeutic Approach : This study proposes a novel strategy combining anti - EGFR targeted therapies and ICIs for treating locally advanced high - grade parotid MEC. • Rationale for Combination Therapy : Given the success of EGFR - targeted therapies and ICIs in other head - and - neck cancers, this research explores their potential synergy against the aggressive high - grade MEC. • Preliminary Findings : Preliminary results show that the combination therapy may exhibit significant antitumor activity and improve survival in patients with locally advanced high - grade parotid MEC, meeting a crucial unmet need. • Translational Impact : The study's findings can potentially inform clinical practice, guide new treatment protocols for malignant salivary gland tumors, and ultimately enhance patient care and outcomes.